Hepatitis C Virus Clinical Trial
Official title:
Prevalence of Seroconversion of Hepatitis c Virus Among Children With Chronic Kidney Disease on Regular Hemodialysis
observational cross sectional study for children with chronic kidney disease who on regular hemodialysis in assiut univeristy children hospital at dialysis unit, observe prevalence of serological seroconversion of hepatitis c virus and associated risk factors
Status | Not yet recruiting |
Enrollment | 50 |
Est. completion date | March 31, 2025 |
Est. primary completion date | December 31, 2024 |
Accepts healthy volunteers | |
Gender | All |
Age group | 1 Year to 18 Years |
Eligibility | Inclusion Criteria: 1. Age: from 1 year to 18 years 2. CKD children on regular hemodialysis for more than one month duration Exclusion Criteria: - 1-Age: less than 1 year and more than 18 years 2- CKD children who are not on regular hemodialysis and for less than one month duration |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Assiut University |
El-Shabrawi MH, Kamal NM. Burden of pediatric hepatitis C. World J Gastroenterol. 2013 Nov 28;19(44):7880-8. doi: 10.3748/wjg.v19.i44.7880. — View Citation
Kosaraju K, Faujdar SS, Singh A, Prabhu R. Hepatitis viruses in heamodialysis patients: an added insult to injury? Hepat Res Treat. 2013;2013:860514. doi: 10.1155/2013/860514. Epub 2013 Mar 6. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Prevalence of Seroconversion of Hepatitis c Virus Among Children With CKD on Regular Hemodialysis | determine prevalence and risk factors associated with seroconversion of hepatitis c in CKD children on regular hemodialysis | Baseline |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02907996 -
Evaluate the Safety and Effectiveness of Sovaldi in Participants With Chronic Hepatitis C Virus (HCV) Infection in Korea
|
||
Completed |
NCT02207088 -
Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney Disease
|
Phase 3 | |
Not yet recruiting |
NCT02893046 -
HCV Care Pathway in Ile-de-France
|
N/A | |
Completed |
NCT01428063 -
Study With PegInterferon Alfa-2a, Ribavirin and BMS-790052 With or Without BMS-650032 for Participants in Some Hepatitis C Virus (HCV) Trials
|
Phase 2 | |
Completed |
NCT01396005 -
A Study to Evaluate the Pharmacokinetic Effect of SCH 503034 (Boceprevir) on Methadone or Buprenorphine/Naloxone Plasma Concentrations (P08123)
|
Phase 1 | |
Completed |
NCT01195181 -
Different PEG-interferon and Ribavirin Schedules for Chronic Hepatitis C in the Real Clinical Practice.
|
Phase 4 | |
Completed |
NCT00219999 -
Hepatitis C Virus and the Humoral Immune System
|
N/A | |
Completed |
NCT02243293 -
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection
|
Phase 2/Phase 3 | |
Completed |
NCT02265237 -
A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir Co-administered With Ribavirin (RBV) in Adults With Genotype 4 Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis (AGATE-1)
|
Phase 3 | |
Completed |
NCT02604017 -
A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Subjects With Genotype 1 Infection
|
Phase 3 | |
Withdrawn |
NCT00947245 -
Japanese Bridging Study Conducted in the United States
|
Phase 1 | |
Completed |
NCT01713283 -
Sofosbuvir Plus Ribavirin in Treatment-Naive and Treatment-Experienced Egyptian Adults With Chronic Genotype 4 Hepatitis C Virus (HCV) Infection
|
Phase 2 | |
Completed |
NCT01479881 -
A Study in Healthy Participants Investigating the Effect of TMC435 on the Pharmacokinetics of Immunosuppressants Cyclosporine and Tacrolimus
|
Phase 1 | |
Completed |
NCT01458535 -
A Study to Evaluate ABT-450 With Ritonavir (ABT-450/r) When Given Together With ABT-267 and With and Without Ribavirin (RBV) in Treatment-Naïve Subjects With Genotype 1, 2 or 3 Chronic Hepatitis C Virus (HCV)
|
Phase 2 | |
Completed |
NCT01193361 -
Ph IIA Study (SOC +/- NS5B)
|
Phase 2 | |
Completed |
NCT01241773 -
TMC435-TiDP16-C123 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC435 and the Antiretroviral Agents Efavirenz and Raltegravir
|
Phase 1 | |
Completed |
NCT01006031 -
Retreatment With High Doses of pegIFN Alfa-2a and Ribavirin of Previous Nonresponders HIV-coinfected Patients With Cirrhosis Due to HCV 1-4
|
Phase 2/Phase 3 | |
Completed |
NCT00819026 -
Observational Trial of Hepatitis C Virus Infected Patients on Calcineurin Inhibitors
|
N/A | |
Completed |
NCT00382798 -
Adaptive Phase I HCV Study With Nucleoside Analogue, in Combination With Interferon and Ribavirin
|
Phase 1/Phase 2 | |
Completed |
NCT02592057 -
Safety and Efficacy of Sofosbuvir-based Regimens in Clinical Practice for the Treatment of Chronic Hepatitis C Virus Infection in India
|